Evidence map›Paper›PMID 41071200›Full record

ArticleMolecular biology reports2025

Clinical, biochemical, and molecular characterization of a cohort of Egyptian patients with Sanfilippo B syndrome (MPS IIIB): Bayesian Gaussian mixture model.

Ekram Fateen, Soha S Nosier, Amira M Radwan, Eman E A Mohammed

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ekram FateenBiochemical Genetics Department, Human Genetics, and Genome Research Institute, National Research Centre, Cairo, Egypt.
Soha S NosierMedical Biochemistry Department, Faculty of Medicine, Damietta University, Damietta, Egypt.
Amira M RadwanBiochemical Genetics Department, Human Genetics, and Genome Research Institute, National Research Centre, Cairo, Egypt.
Eman E A MohammedMedical Molecular Genetics Department, Human Genetics, and Genome Research Institute, National Research Centre, Cairo, Egypt. em.mohammed99@gmail.comEmail.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLysosomal storage diseases (LSDs) are a group of genetically heterogeneous inherited metabolic disorders that affect the functions of the lysosomes in different human tissues. Mucopolysaccharidosis IIIB (MPS IIIB), Sanfilippo B syndrome, is an autosomal recessive LSD characterized by a deficiency of the lysosomal enzyme α-N-acetylglucosaminidase. This study aims to investigate the molecular genetic spectrum of α-N-acetyl-glucosaminidase (NAGLU) variants, as well as their biochemical and clinical characteristics, in a cohort of MPS IIIB Egyptian patients. This study aims to expand the characterization of biochemical and molecular spectrum profiles of MPSIIIB in Egyptian patients since this monogenic disease seems commonly encountered in our population. PATIENTS AND

methodsA cohort of eleven children from unrelated Egyptian families, clinically and biochemically diagnosed with MPS IIIB based on heparan sulphate accumulation, were enrolled in the present study. Patients variably presented with early-onset, progressive neurological and mental deterioration, aggressive and hyperactive behaviors, sleep disturbances, and hepatosplenomegaly. Bayesian Gaussian Mixture machine learning (ML) model, an in-silico prediction tool, protein modelling, and thermodynamic stability predictions were applied to assess the functional consequences, and the potential clinical impact of two missense variants, recently reported .

resultsSanger sequencing of the NAGLU coding and exon-intron boundaries revealed seven different homozygous disease-causing variants [p.(Leu348Arg), p.(Val117Leu), p.(Trp268Arg), p.(Glu452Lys), p.(Arg482Trp), p.(Arg482Gln), and p.(Leu550Pro)] The most frequently encountered variant was the p.(Arg482Trp) (12/22; 37%) located in exon 6, followed by the missense variant p.(Trp268Arg) (4/22; 18%) in exon 5, while the other three missense variants, p.(Glu452Lys), p.(Arg482Gln), and p.(Leu550Pro)] each appeared in only one patient, representing 9% of the disease-causing variants. Sixteen mutant alleles (16/22; 72%) were identified in NAGLU exon 6, indicating that exon 6 is a hotspot in Egyptian Sanfilippo B patients. In silico analysis using multiple computational tools and the Bayesian Gaussian Mixture ML model for assessment of missense variants predicted the p.(Leu348Arg) missense variant to be deleterious and destabilizing the protein structure. In contrast, the p.(Val117Leu) missense variant was consistently predicted to have a stabilizing effect on the protein.

conclusionsThis study expands the molecular genetic spectrum of the NAGLU mutations associated with MPS IIIB in Egyptian patients. The study results highlight exon 6 as a hot-spot for the first screening of NAGLU gene in Egyptian families with MPS IIIB. This will promote the early diagnosis and genetic counselling for patients and their families in Egypt. The application of a machine learning (ML) model to assess missense variants identified in our Egyptian patients provided significant insights into their clinical impact and the observed variable clinical severity. The use of AMCMG criteria and in silico tools to predict the pathogenicity and protein stability changes of these variants proved valuable and demonstrated the utility of computational methods in assessing the clinical relevance of genetic variants.

Indexed as

AcetylglucosaminidaseMucopolysaccharidosis IIIAdolescentBayes TheoremChildChild, PreschoolCohort StudiesEgyptFemaleHumansInfantMaleMutationAcetylglucosaminidasealpha-N-acetyl-D-glucosaminidaseMPS IIIBMucopolysaccharidosis IIIBNAGLU geneSanfilippo b syndromeα-N-acetyl-D-glucosaminidase gene

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.